comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 20:48:40 - browse：77652

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： President Biden's budget: Here's what you might have missed

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

People can get long Covid without testing positive for virus: Study

Why depression after traumatic brain injury is distinct

FDA advisory panel to debate high blood pressure devices

FDA advisory panel to debate high blood pressure devices

focus

comprehensive

explore

Duchenne breakthrough therapy leaves behind pioneering families

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wildfire smoke exposes gaps in outdoor worker protections

People can get long Covid without testing positive for virus: Study

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Supreme Court strikes down use of affirmative action

President Biden's budget: Here's what you might have missed

The high cost of giving birth even with insurance

Study: Spinal cord stimulation helps patients with paralysis walk again

focus

Change Healthcare outage fallout shows need for new oversight

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Intellia plays down concerns on accidental germline transmission

FDA advisory panel to debate high blood pressure devices

FDA advisory panel to debate high blood pressure devices

Meadows told special counsel he could not recall Trump ever declassifying Mar

focus

hotspot

hotspot

knowledge